Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054909 · ClinicalTrials.gov registry record · Phase 2
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03054909 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants.
The verdict
NCT03054909, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.
Interventions
- BIOLOGICAL ALT-803 Subcutaneous
- BIOLOGICAL ALT-803 Intraperitoneal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03054909
The ClinicalTrials.gov registry entry for NCT03054909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALT-803 Subcutaneous is the first listed.
NCT03054909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03054909 about?
NCT03054909 is a clinical study titled "IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer". This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.
What is the current status of trial NCT03054909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2017-09-19. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT03054909?
The interventions under investigation include: ALT-803 Subcutaneous (BIOLOGICAL), ALT-803 Intraperitoneal (BIOLOGICAL).
Who is sponsoring clinical trial NCT03054909?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.